LifeVantage Stock Performance
LFVN opened at $3.89 on Tuesday. The company has a 50-day moving average of $3.80 and a 200-day moving average of $3.92. The company has a market capitalization of $48.89 million, a P/E ratio of 97.25 and a beta of 1.10. LifeVantage has a 1-year low of $3.46 and a 1-year high of $6.68.
LifeVantage (NASDAQ:LFVN – Get Rating) last released its earnings results on Wednesday, November 2nd. The company reported $0.06 earnings per share for the quarter. LifeVantage had a net margin of 0.20% and a return on equity of 9.48%. The company had revenue of $51.77 million during the quarter. As a group, sell-side analysts expect that LifeVantage will post 0.33 earnings per share for the current fiscal year.
Institutional Investors Weigh In On LifeVantage
LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive and immune system function; a line of weight management products under the PhysIQ brand; IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes.
- Get a free copy of the StockNews.com research report on LifeVantage (LFVN)
- Is Macau a Sinking Ship for Wynn Resorts?
- Don’t Miss These 2 Mid-Cap Techs That Broke Out Last Week
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
- Why Warner Bros Discovery Is the S&P’s Hottest Stock
- Pinterest is the Social Commerce Platform to Watch in 2023
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.